Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 16, 2005

Primary Completion Date

October 18, 2018

Study Completion Date

April 24, 2026

Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaRecurrent Adult Brain Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Temozolomide

Given orally

DRUG

Vorinostat

Given orally

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

20892

National Cancer Institute Neuro-Oncology Branch, Bethesda

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

35233

University of Alabama at Birmingham Cancer Center, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

77030

M D Anderson Cancer Center, Houston

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94115

UCSF Medical Center-Mount Zion, San Francisco

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH